Payment overview · 2025
General Payments
$95.79
4 reported records · 3 companies
Healthcare provider profile · identity verified
Steven Wayne Johnson, DO
Allopathic & Osteopathic Physicians|Family Medicine · SEVIERVILLE, TN · NPI 1700853058
Verified facts
What the public records show
CMS Open Payments records show Steven Wayne Johnson, DO received $95.79 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 53.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $51.56 | 53.8% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $28.62 | 29.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.61 | 16.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.79 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.56 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $28.62 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 77 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 545 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 301 | 80 |
| Methylprednisolone | Methylprednisolone | 261 | 132 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 243 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 235 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 234 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 63 |
| Trazodone Hcl | Trazodone Hcl | 226 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 216 | 61 |
| Montelukast Sodium | Montelukast Sodium | 202 | 60 |
| Losartan Potassium | Losartan Potassium | 175 | 51 |
| Pregabalin | Pregabalin | 173 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 164 | 64 |
| Lisinopril | Lisinopril | 159 | 43 |
| Famotidine | Famotidine | 157 | 53 |
| Omeprazole | Omeprazole | 150 | 40 |
| Azithromycin | Azithromycin | 149 | 99 |
| Furosemide | Furosemide | 149 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 146 | 26 |
| Topiramate | Topiramate | 145 | 33 |
| Alprazolam | Alprazolam | 143 | 21 |
| Metformin Hcl | Metformin Hcl | 139 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 35 |
| Tramadol Hcl | Tramadol Hcl | 128 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 126 | 76 |
| Potassium Chloride | Potassium Chloride | 125 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 56 |
| Clonazepam | Clonazepam | 121 | 15 |
| Lorazepam | Lorazepam | 121 | 34 |
| Meloxicam | Meloxicam | 120 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 117 | 31 |
| Diazepam | Diazepam | 104 | 21 |
| Donepezil Hcl | Donepezil Hcl | 103 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 27 |
| Finasteride | Finasteride | 97 | 22 |
| Methocarbamol | Methocarbamol | 94 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 29 |
| Carvedilol | Carvedilol | 89 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 89 | 21 |
| Simvastatin | Simvastatin | 86 | 17 |
| Sucralfate | Sucralfate | 86 | 29 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 81 | 23 |
| Ondansetron Odt | Ondansetron | 80 | 37 |
| Ozempic | Semaglutide | 77 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 23 |
| Sumatriptan Succinate | Sumatriptan Succinate | 69 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 18 |
| Metformin Hcl Er | Metformin Hcl | 62 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 61 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 17 |
| Atenolol | Atenolol | 57 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 19 |
| Mirtazapine | Mirtazapine | 57 | 23 |
| Allopurinol | Allopurinol | 56 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 12 |
| Baclofen | Baclofen | 54 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 14 |
| Jardiance | Empagliflozin | 53 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 53 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 50 | 24 |
| Eliquis | Apixaban | 49 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 14 |
| Sertraline Hcl | Sertraline Hcl | 47 | 13 |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 46 | 11 |
| Cefdinir | Cefdinir | 45 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | 14 |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Ramipril | Ramipril | 40 | suppressed |
| Fluconazole | Fluconazole | 39 | 19 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Lactulose | Lactulose | 31 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Meclizine Hcl | Meclizine Hcl | 30 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Azelastine Hcl | Azelastine Hcl | 28 | 13 |
| Nystatin | Nystatin | 28 | 20 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | 11 |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Prednisone | Prednisone | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Cilostazol | Cilostazol | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.79 · 4 records | PFIZER INC. | DAYBUE, NURTEC ODT, Ozempic, Rybelsus, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error